A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed 454 enrolled Amgen

RandomizedParallel-groupOpen-labelTreatment

Summary

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

Timeline

Start: 2019-05-08
Primary completion: 2023-03-31
Completion: 2023-03-31

Publications

Dimopoulos MA, Coriu D, Delimpasi S, Spicka I, Upchurch T, Fang B, Talpur R, Faber E, Beksac M, Leleu X. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Blood Adv. 2024 Oct 8;8(19):5012-5021. doi: 10.1182/bloodadvances.2024013101.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Carfilzomib	Other / unclassified	27 mg/m2	Intravenous
Comparator	Carfilzomib	Other / unclassified	56 mg/m2	Intravenous
Comparator	Dexamethasone	Small molecule	40 mg	Oral
Comparator	Lenalidomide	Other / unclassified	25 mg	Oral

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications